Myeloid cell leukemia-1 is a molecular indicator for malignant transformation of oral lichen planus

Shin,Ji‑Ae; Seo,Jae‑Min; Oh,Sejun; Cho,Sung‑Dae; Lee,Kyung‑Eun

doi:10.3892/ol.2016.4083

Myeloid cell leukemia-1 is a molecular indicator for malignant transformation of oral lichen planus

Authors:
- Ji‑Ae Shin
- Jae‑Min Seo
- Sejun Oh
- Sung‑Dae Cho
- Kyung‑Eun Lee
View Affiliations

Affiliations: Department of Oral Pathology, School of Dentistry and Institute of Biodegradable Material, Institute of Oral Bioscience, Brain Korea 21 Project, Chonbuk National University, Jeonju 561‑756, Republic of Korea, Department of Prosthodontics, School of Dentistry and Institute of Oral Bioscience, Biomedical Research Institute, Chonbuk National University, Jeonju 561‑756, Republic of Korea, Department of Oral Medicine, School of Dentistry, Institute of Oral Bioscience, Chonbuk National University, Jeonju 561‑756, Republic of Korea
Published online on: January 8, 2016 https://doi.org/10.3892/ol.2016.4083
Pages: 1603-1607

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral lichen planus (OLP), characterized by a chronic mucocutaneous inflammatory condition, is a common disease of the oral cavity. Retrospective and prospective epidemiological data suggest that OLP is considered to have malignant potential. However, it is unclear as to which types of molecules may cause malignant transformation of OLP. In the present study, the presence of myeloid cell leukemia‑1 (Mcl‑1) and B‑cell lymphoma‑2 (Bcl‑2) was studied by western blot analysis in 11 OLP and three normal oral mucosa (NOM) samples and in two human oral cancer cell lines. The functional role of Mcl‑1 in oral cancer cells was analyzed using a trypan blue exclusion assay and soft agar assay. Mcl‑1 was strongly expressed in the OLP and the two oral cancer cell lines compared with NOM, whereas Bcl‑2 was not. Sorafenib and mithramycin A decreased cell viability in MC‑3 and HSC‑3 oral cancer cells and at same concentration they reduced the expression level of Mcl‑1 in the two cell lines. The two chemicals affected Mcl‑1 protein and significantly inhibited neoplastic cell transformation in the two cell lines. We suggest that the malignant potential of OLP may be associated with the expression of Mcl‑1, and that downregulation of Mcl‑1 may prevent malignant transformation of OLP to oral cancer.

View Figures

View References

1	Barnes L, Eveson JW, Reichart P and Sidransky D: Tumor of the oral cavity and oropharynx. Pathology and Genetics of Head and Neck Tumours (World Health Organization Classification of Tumours) (Lyon). IARC Press. 2005.
2	Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH and Shukla A: Pathogenesis of oral lichen planus - a review. J Oral Pathol Med. 39:729–734. 2010. View Article : Google Scholar : PubMed/NCBI
3	Farhi D and Dupin N: Pathophysiology, etiologic factors and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol. 28:100–108. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ismail SB, Kumar SK and Zain RB: Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 49:89–106. 2007. View Article : Google Scholar : PubMed/NCBI
5	Parashar P: Oral lichen planus. Otolaryngol Clin North Am. 44:89–107. 2011. View Article : Google Scholar : PubMed/NCBI
6	McCartan BE and Healy CM: The reported prevalence of oral lichen planus: a review and critique. J Oral Pathol Med. 37:447–453. 2008. View Article : Google Scholar : PubMed/NCBI
7	Kramer IR, Lucas RB, Pindborg JJ and Sobin LH: Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol. 46:518–539. 1978. View Article : Google Scholar : PubMed/NCBI
8	Silverman S Jr..Gorsky M and Lozada-Nur F: A prospective follow-up study of 570 patients with oral lichen planus: persistence, remission and malignant association. Oral Surg Oral Med Oral Pathol. 60:30–34. 1985. View Article : Google Scholar : PubMed/NCBI
9	Murti PR, Daftary DK, Bhonsle RB, Gupta PC, Mehta FS and Pindborg JJ: Malignant potential of oral lichen planus: observations in 722 patients from India. J Oral Pathol. 15:71–77. 1986. View Article : Google Scholar : PubMed/NCBI
10	Silverman S Jr, Gorsky M, Lozada-Nur F and Giannotti K: A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 72:665–670. 1991. View Article : Google Scholar : PubMed/NCBI
11	Sigurgeirsson B and Lindelöf B: Lichen planus and malignancy. An epidemiologic study of 2071 patients and a review of the literature. Arch Dermatol. 127:1684–1688. 1991. View Article : Google Scholar : PubMed/NCBI
12	van der Meij EH, Mast H and van der Waal I: The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. Oral Oncol. 43:742–748. 2007. View Article : Google Scholar : PubMed/NCBI
13	Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L and Bucci E: Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol. 40:120–130. 2004. View Article : Google Scholar : PubMed/NCBI
14	Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB and Thongprasom K: Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 100:164–178. 2005. View Article : Google Scholar : PubMed/NCBI
15	Sousa FA, Paradella TC, Carvalho YR and Rosa LE: Immunohistochemical expression of PCNA, p53, bax and bcl-2 in oral lichen planus and epithelial dysplasia. J Oral Sci. 51:117–121. 2009. View Article : Google Scholar : PubMed/NCBI
16	de Sousa FA, Paradella TC, Carvalho YR and Rosa LE: Comparative analysis of the expression of proliferating cell nuclear antigen, p53, bax and bcl-2 in oral lichen planus and oral squamous cell carcinoma. Ann Diagn Pathol. 13:308–312. 2009. View Article : Google Scholar : PubMed/NCBI
17	Nagata S: Apoptosis by death factor. Cell. 88:355–365. 1997. View Article : Google Scholar : PubMed/NCBI
18	Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR and Newmeyer DD: BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 17:525–535. 2005. View Article : Google Scholar : PubMed/NCBI
19	Jordan RC, Catzavelos GC, Barrett AW and Speight PM: Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol. 32B:394–400. 1996. View Article : Google Scholar : PubMed/NCBI
20	Singh BB, Chandler FW Jr, Whitaker SB and Forbes-Nelson AE: Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 85:692–698. 1998. View Article : Google Scholar : PubMed/NCBI
21	Sulkowska M, Famulski W, Chyczewski L and Sulkowski S: Evaluation of p53 and bcl-2 oncoprotein expression in precancerous lesions of the oral cavity. Neoplasma. 48:94–98. 2001.PubMed/NCBI
22	Warr MR and Shore GC: Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med. 8:138–147. 2008. View Article : Google Scholar : PubMed/NCBI
23	Mallick S, Patil R, Gyanchandani R, Pawar S, Palve V, Kannan S, Pathak KA, Choudhary M and Teni TR: Human oral cancers have altered expression of Bcl-2 family members and increased expression of the anti-apoptotic splice variant of Mcl-1. J Pathol. 217:398–407. 2009. View Article : Google Scholar : PubMed/NCBI
24	Shin JA, Jung JY, Ryu MH, Safe S and Cho SD: Mithramycin A inhibits myeloid cell leukemia-1 to induce apoptosis in oral squamous cell carcinomas and tumor xenograft through activation of Bax and oligomerization. Mol Pharmacol. 83:33–41. 2013. View Article : Google Scholar : PubMed/NCBI
25	Leyva-Huerta ER, Ledesma-Montes C, Rojo-Botello RE and Vega-Memije E: P53 and bcl-2 immunoexpression in patients with oral lichen planus and oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 17:e745–e750. 2012. View Article : Google Scholar : PubMed/NCBI
26	Nagata M, Wada K, Nakajima A, Nakajima N, Kusayama M, Masuda T, Iida S, Okura M, Kogo M and Kamisaki Y: Role of myeloid cell leukemia-1 in cell growth of squamous cell carcinoma. J Pharmacol Sci. 110:344–353. 2009. View Article : Google Scholar : PubMed/NCBI
27	Huang S, Okumura K and Sinicrope FA: BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res. 15:150–159. 2009. View Article : Google Scholar : PubMed/NCBI
28	Rahmani M, Davis EM, Bauer C, Dent P and Grant S: Apoptosis induced by the kinase inhibitor BAY 43–9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 280:35217–35227. 2005. View Article : Google Scholar : PubMed/NCBI
29	Yu HJ, Shin JA, Jung JY, Nam JS, Hong IS, Cho NP and Cho SD: Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft. Head Neck. 37:1326–1335. 2015. View Article : Google Scholar : PubMed/NCBI